| Year |
Citation |
Score |
| 2013 |
Bussel JB, Saleh MN, Vasey SY, Mayer B, Arning M, Stone NL. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). British Journal of Haematology. 160: 538-46. PMID 23278590 DOI: 10.1111/Bjh.12169 |
0.339 |
|
| 2013 |
Platzbecker U, Wong RS, Verma A, Abboud CN, Araujo S, Chiou T, Feigert J, Yeh S, Götze K, Gorin NC, Greenberg PL, Kambhampati S, Kim YJ, Lee J, Lyons RM, ... ... Stone NL, et al. Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy Blood. 122: 5214-5214. DOI: 10.1182/Blood.V122.21.5214.5214 |
0.328 |
|
| 2012 |
Mittelman M, Assouline S, Briasoulis E, Alonso A, Delgado RG, O'Gorman P, Kim HJ, Yoon S, Zaritskey A, Flynn CM, Min Y, Diez-Campelo M, Myasnikov A, Mannino F, Kamel YM, ... ... Stone NL, et al. Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study Blood. 120: 3822-3822. DOI: 10.1182/Blood.V120.21.3822.3822 |
0.344 |
|
| 2011 |
Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet (London, England). 377: 393-402. PMID 20739054 DOI: 10.1016/S0140-6736(10)60959-2 |
0.324 |
|
| 2009 |
Cheng G, Tarantino M, Gernsheimer T, Meyer O, Brainsky A, Stone NL. Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura. Blood. 114: 3517-3517. DOI: 10.1182/Blood.V114.22.3517.3517 |
0.331 |
|
| 2008 |
Saleh MN, Bussel JB, Cheng G, Meddeb B, Burgess PM, De Obaldia ME, Stone NL, Aivado M. Eltrombopag Is Efficacious in Patients with Refractory Chronic Idiopathic Thrombocytopenic Purpura (ITP) - Data from the EXTEND Study Blood. 112: 401-401. DOI: 10.1182/Blood.V112.11.401.401 |
0.331 |
|
| 2008 |
Cheng G, Saleh MN, Bussel JB, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL. Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE) Blood. 112: 400-400. DOI: 10.1182/Blood.V112.11.400.400 |
0.351 |
|
| 2008 |
Bussel JB, Cheng G, Saleh MN, Meddeb B, Bailey C, Stone NL, Aivado M. Safety and Efficacy of Long-Term Treatment with Oral Eltrombopag for Chronic Idiopathic Thrombocytopenic Purpura. Blood. 112: 3432-3432. DOI: 10.1182/Blood.V112.11.3432.3432 |
0.358 |
|
| 2008 |
Bussel JB, Psaila B, Saleh MN, Vasey S, Mayer B, Stone NL, Arning M. Efficacy and Safety of Repeated Intermittent Treatment with Eltrombopag in Patients with Chronic Idiopathic Thrombocytopenic Purpura. Blood. 112: 3431-3431. DOI: 10.1182/Blood.V112.11.3431.3431 |
0.362 |
|
| 2008 |
Cheng G, Bussel JB, Saleh MN, Meddeb B, De Obaldia ME, Aivado M, Stone NL. Eltrombopag Delivers Clinical Benefit in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients Not Achieving Platelet Counts ≥50,000/μL - Data from the EXTEND Study. Blood. 112: 3430-3430. DOI: 10.1182/Blood.V112.11.3430.3430 |
0.318 |
|
| 2007 |
Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. The New England Journal of Medicine. 357: 2237-47. PMID 18046028 DOI: 10.1056/Nejmoa073275 |
0.311 |
|
| 2006 |
Orlando KA, Stone NL, Pittman RN. Rho kinase regulates fragmentation and phagocytosis of apoptotic cells. Experimental Cell Research. 312: 5-15. PMID 16259978 DOI: 10.1016/J.Yexcr.2005.09.012 |
0.487 |
|
| 2006 |
Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, Jenkins J, Provan A. Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor. Blood. 108: 475-475. DOI: 10.1182/Blood.V108.11.475.475 |
0.311 |
|
| 2001 |
Qi H, Juo P, Masuda-Robens J, Caloca MJ, Zhou H, Stone N, Kazanietz MG, Chou MM. Caspase-mediated cleavage of the TIAM1 guanine nucleotide exchange factor during apoptosis. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 12: 603-11. PMID 11751455 |
0.331 |
|
| 1999 |
Mills JC, Stone NL, Pittman RN. Extranuclear apoptosis. The role of the cytoplasm in the execution phase. The Journal of Cell Biology. 146: 703-8. PMID 10459006 DOI: 10.1083/Jcb.146.4.703 |
0.562 |
|
| 1998 |
Erhardt JA, Hynicka W, DiBenedetto A, Shen N, Stone N, Paulson H, Pittman RN. A novel F box protein, NFB42, is highly enriched in neurons and induces growth arrest. The Journal of Biological Chemistry. 273: 35222-7. PMID 9857061 DOI: 10.1074/Jbc.273.52.35222 |
0.558 |
|
| 1998 |
Mills JC, Stone NL, Erhardt J, Pittman RN. Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation. The Journal of Cell Biology. 140: 627-36. PMID 9456322 DOI: 10.1083/Jcb.140.3.627 |
0.595 |
|
| Show low-probability matches. |